A Comprehensive Narrative Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical

**Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis** 

**Authors** 

Bruce W Kirkham<sup>1</sup>, Alexander Egeberg<sup>2,3</sup>, Frank Behrens<sup>4</sup>, Andreas Pinter<sup>5</sup>, Joseph F Merola<sup>6</sup>,

Thorsten Holzkämper<sup>7</sup>, Gaia Gallo<sup>7</sup>, Khai Jing Ng<sup>7</sup>, Rebecca Bolce<sup>7</sup>, Christopher Schuster<sup>7,8</sup>, Peter

Nash<sup>9</sup>, Luis Puig<sup>10</sup>.

**Author Affiliations** 

<sup>1</sup> Guy's and St Thomas' NHS Foundation Trust, London, UK

<sup>2</sup> Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark

<sup>3</sup> Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

<sup>4</sup> Rheumatology Department University Hospital and Fraunhofer Institute for Translational Medicine

& Pharmacology ITMP, Fraunhofer Cluster of Excellence Immune-Mediated Diseases, Goethe

University Frankfurt, Frankfurt am Main, Germany

<sup>5</sup> Department of Dermatology, Venereology and Allergology, University Hospital Frankfurt, Frankfurt

am Main, Germany

<sup>6</sup> Dermatology and Medicine, Division of Rheumatology and Immunology, Brigham and Women's

Hospital, Harvard Medical School, Boston, Massachusetts, USA

<sup>7</sup> Eli Lilly and Company, Indianapolis, Indiana, USA

<sup>8</sup> Department of Dermatology, Medical University of Vienna, Vienna, Austria

<sup>9</sup> Department of Medicine, University of Queensland, Rheumatology Research Unit, Sunshine Coast,

Queensland, Australia

<sup>10</sup> Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de


Barcelona, Barcelona, Spain


**Corresponding Author:** Bruce W Kirkham (<u>bruce.kirkham@gstt.nhs.uk</u>)


Address: Guy's and St Thomas' NHS Foundation Trust, London, UK

Email: bruce.kirkham@gstt.nhs.uk


**Supplemental Figure 1:** Summary of nail psoriasis data across IXE trials in patients with PsO with concomitant nail psoriasis at baseline





















**Supplemental Figure 2:** Summary of nail psoriasis data across IXE trials in patients with PsA with concomitant nail psoriasis at baseline











IXE Q4W

